Key facts
- Brainify.AI’s last known valuation is $24.0M (Feb 2026).
- It has raised $5.5M; the latest was Early Stage VC ($1.5M) in Feb 2026.
- Notable investors include Johnson & Johnson Innovation - JLABS, MSD Global Health Innovation Fund, Esther Dyson, Ivan Nechaev, Kodori — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Brainify.AI
- ·The full record, as it builds
Funding rounds
No funding rounds for Brainify.AI are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Brainify.AI
Developer of brain data technology designed to support precision medicine for disorders of the brain. The company offers methods for converting brain data into objective and deployable biomarkers, enabling biopharmaceutical companies and healthcare providers to assess brain function, group patients appropriately, and tailor treatment decisions across psychiatry, neurology, and neurodegenerative care.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2021
- Employees
- 11
- Website
- brainify.ai/
- Ownership
- Privately Held (backing)
Brainify.AI doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Brainify.AI shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Brainify.AI in its N-PORT filings yet. We sweep new filings monthly.